Stay updated on MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.

Latest updates to the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2; a minor technical update with no changes to study data.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision metadata updated: added revision note for v3.5.0. The previous v3.4.3 revision entry was removed.SummaryDifference0.0%

- Check41 days agoChange DetectedAdded revision v3.4.3 and removed revision v3.4.2.SummaryDifference0.1%

- Check48 days agoChange DetectedThe screenshots show the same study details with no additions or deletions detected.SummaryDifference0.0%

- Check56 days agoChange DetectedThe trial record now indicates Terminated status and a new Phase 1 SOS1 inhibitor study of MRTX0902 with 64 participants, including Phase 1 dose escalation and expansion cohorts, replacing prior Phase 1/2 entries.SummaryDifference2%

- Check70 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1.SummaryDifference0.4%

Stay in the know with updates to MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.